GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features.
Neuromolecular Med. 2016 Jun 9. [Epub ahead of print]
Gezen-Ak D1, Alaylıoğlu M2, Genç G3, Gündüz A4, Candaş E2, Bilgiç B5, Atasoy İL2, Apaydın H4, Kızıltan G4, Gürvit H5, Hanağası H5, Ertan S4, Yılmazer S2, Dursun E6.
- 2X more Parkinson's disease if modified vitamin D receptor genes – meta-analysis Aug 2014
- CYP2R1 and GC variations decrease vitamin D response – PHD thesis Nov 2015
- Benefits of Vitamin D often limited by genes
- All items in Vitamin D Binding Protein (GC) and vitamin D
141 items The items in both Parkinson's Disease and Vitamin D Binding Protein categories are listed here:
The items in both Parkinson's Disease and Vitamin D Receptor categories are listed here:
- Parkinson’s disease 1.6X more likely if a poor Vitamin D Receptor – meta-analysis Jan 2020
- Parkinson’s disease 20 percent more likely in Asians if poor Vitamin D Receptor – meta-analysis April 2019
- Parkinson's disease cognitive decline associated with poor Vitamin D receptor – Nov 2016
- Parkinson’s risk increased 2 to 7 times depending on Vitamin D Receptor – Sept 2016
- Parkinson's Disease associations with Vitamin D receptor and GC gene (behind paywall) – June 2016
- 2X more Parkinson's disease if modified vitamin D receptor genes – meta-analysis Aug 2014
- Parkinson's and Alzheimer's: associations with vitamin D receptor genes and race – meta-analysis July 2014
Overview Parkinsons and Vitamin D contains the following summary
Parkinson's Disease proven to be TREATED by Vitamin D (Many Meta-analyses of trials)- Parkinson's disease stabilized with just 1200 IU of vitamin D – RCT May 2013
First RCT to report results - +anticipate far better results when more vitamin D is used.
(Belief based on the results with vitamin D on MS and Diabetes)
Additonal proofs that vitamin D treats or prevents diseases - 6 clinical trials for PD with vitamin D intervention as of Jan 2016
A person could wait a few years to get the results of the clinical trials, but - Based on reading more than 4,000 studies of vitamin D at Vitamin D Life
- A (loading) dose of 20,000 IU of vitamin D daily for the 3 weeks should provide observable benefit
To avoid a rare reaction to Vitamin D
take 1,000 IU of vitamin D first, and stop if you you have an allergic reaction withiin 3 days
When continuing to take vitamin D you should also take cofactors
There is virtually no need have a vitamin D test in first 2 months - Parkinson's category has
82 items - All items in sub category Vitamin D Receptor
384 items - Genetics category listing has
266 items along with related searches has the following Many genes are NOT noticed by Vitamin D measurements
Publisher wants $40 for the PDF
1Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098, Istanbul, Turkey. duygugezenak at gmail.com.
2Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098, Istanbul, Turkey.
3Department of Neurology, Gumussuyu Military Hospital, Istanbul, Turkey.
4Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
5Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
6Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098, Istanbul, Turkey. erdincdu at yahoo.com.Vitamin D deficiency is suggested to be associated with Parkinson's disease (PD). Our aim was to investigate the serum 25-hydroxyvitamin D3 (25OHD) levels of PD patients in Turkish cohort, to investigate any association of vitamin D binding protein (GC) genotypes with PD due to the significant role of GC in vitamin D transport, to determine whether vitamin D receptor (VDR) haplotype that we previously demonstrated to be a risk haplotype for AD is also a common haplotype for PD and to investigate any relevant consequence of serum 25OHD levels, GC or VDR genotypes on clinical features of PD.
Three hundred eighty-two PD patients and 242 healthy subjects were included in this study. The serum 25OHD levels were investigated by CLIA, and GC and VDR SNPs were evaluated with LightSnip. Our results indicated a strong relationship between low serum 25OHD levels and PD (p < 0.001). rs7041 of GC and ApaI of VDR were associated with the PD risk (p < 0.05).
Minor allele carriers for BsmI of VDR gene in both PD patients and healthy subjects had significantly higher levels of serum 25OHD (p < 0.05).
The homozygous major allele carriers for rs2282679, rs3755967 and rs2298850 of GC gene in PD patients with slower progression had significantly higher levels of serum 25OHD (p < 0.05).
Minor allele carriers for FokI of VDR gene were more frequent in patients with advanced-stage PD (p < 0.05). Consequently, this is the first study demonstrating GC gene as a risk factor for PD. The relationship between PD's clinical features and low 25OHD or risk genotypes might have effects on PD independently.
PMID: 27282160
Parkinson's Disease associations with Vitamin D receptor and GC gene (behind paywall) – June 2016Printer Friendly PDF this page! Follow this page for updates4136 visitors, last modified 13 Dec, 2019, - Genetics category listing has
- All items in sub category Vitamin D Receptor